Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Public ClinicalTrials.gov record NCT00984217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Standard therapy for high-risk or locally advanced salivary gland malignancies is surgery followed by postoperative radiation therapy. Retrospective studies have shown the superiority of combined modality therapy compared to surgery alone for patients with advanced T or N stage. Despite the addition of postoperative radiation therapy, the five-year survival for locally advanced salivary gland malignancies is poor (less than 60%). In salivary gland malignancies, the epidermal growth factor receptor (EGFR) is expressed in 25-85%; in certain histological types, like salivary duct carcinomas, the expression is higher. EGFR is a promising target of anticancer therapy. In squamous cell carcinoma of the head and neck, a phase III trial utilizing cetuximab added to radiation therapy improved both locoregional control and overall survival compared to radiation alone. Panitumumab is a novel, human, IgG2 EGFR monoclonal antibody that may be better tolerated and more efficacious than cetuximab. Here, the investigators suggest that the addition of panitumumab to standard radiotherapy in locally-advanced salivary gland malignancies will improve recurrence-free survival (RFS).
Study identification
- NCT ID
- NCT00984217
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2011
- Primary completion
- Jul 31, 2011
- Completion
- Jul 31, 2011
- Last update posted
- Jan 7, 2016
2011
United States locations
- U.S. sites
- 27
- U.S. states
- 2
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UPMC Cancer Center - Teramana Cancer Center - Steubenville | Steubenville | Ohio | 43952 | — |
| UPMC Cancer Center - Beaver | Beaver | Pennsylvania | 15009 | — |
| UPMC Cancer Center - Clairton | Clairton | Pennsylvania | 15025 | — |
| UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg | Greensburg | Pennsylvania | 15601 | — |
| UPMC Cancer Center - Oakbrook Commons - Greensburg | Greensburg | Pennsylvania | 15601 | — |
| UPMC Cancer Center - Oakbrook Commons | Greensburg | Pennsylvania | 15601 | — |
| UPMC Cancer Center -Arnold Palmer Pavilion | Greensburg | Pennsylvania | 15601 | — |
| UPMC Cancer Center - Indiana | Indiana | Pennsylvania | 15701 | — |
| UPMC Cancer Center - John P. Murtha Pavilion - Johnstown | Johnstown | Pennsylvania | 15901 | — |
| UPMC Cancer Center - McKeesport | McKeesport | Pennsylvania | 15132 | — |
| UPMC Cancer Center - Monroeville | Monroeville | Pennsylvania | 15146 | — |
| UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group | Moon Township | Pennsylvania | 15108 | — |
| UPMC Cancer Center -Mt. Pleasant | Mount Pleasant | Pennsylvania | 15666 | — |
| UPMC Cancer Center - New Castle | New Castle | Pennsylvania | 16105 | — |
| UPMC Presbyterian -Radiation Oncology | Pittsburgh | Pennsylvania | 15213 | — |
| UPMC Cancer Center - St. Margaret's | Pittsburgh | Pennsylvania | 15215 | — |
| UPMC Cancer Center -Delafield Rd. | Pittsburgh | Pennsylvania | 15215 | — |
| Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Cancer Center -UPMC Shadyside | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Cancer Centers | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Cancer Center - Passavant | Pittsburgh | Pennsylvania | 15237 | — |
| UPMC Cancer Center - Upper St. Clair | Pittsburgh | Pennsylvania | 15241 | — |
| UPMC Cancer Center -Drake | Pittsburgh | Pennsylvania | 15241 | — |
| UPMC Cancer Center -UPMC Northwest | Seneca | Pennsylvania | 16346 | — |
| UPMC Cancer Center - Uniontown | Uniontown | Pennsylvania | 15401 | — |
| UPMC Cancer Center - Washington | Washington | Pennsylvania | 15301 | — |
| UPMC Cancer Center - North Hills | Wexford | Pennsylvania | 15090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00984217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2016 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00984217 live on ClinicalTrials.gov.